High Water Intake in Polycystic Kidney Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-26

Study Completion Date

2018-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

DRINK is an open-label randomised controlled feasibility trial of high versus ad libitum water intake in ADPKD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy Study of Water Drinking on PKD Progression.

NCT01348035

Autosomal Dominant Polycystic Kidney Disease Disease Progression

COMPLETED

High Water Intake to Slow Progression of Polycystic Kidney Disease

NCT00784030

Kidney, Polycystic, Autosomal Dominant

COMPLETED NA

Fluid Intake Application to Reduce Kidney Stone Risks

NCT01928108

Kidney Stone

COMPLETED

Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease

NCT02776241

ADPKD

COMPLETED NA

Effect of Exercise on Renal Function in Predialysis

NCT02155036

Chronic Kidney Disease

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Autosomal Dominant Polycystic Kidney Disease (PKD) affects 12.5 million people worldwide, and accounts for 7% of those requiring renal replacement therapy. The hormone vasopressin drives cyst growth until ultimately most of the normal functioning kidney tissue is replaced and compressed by cysts over the life course. Half of those affected will require dialysis by the age of 55 years.

Vasopressin blockade has emerged as a viable strategy for altering disease course. High water intake suppresses vasopressin, and may therefore slow cyst growth and consequent disease progression. However, evidence to support high water intake in PKD is lacking, and it is not clear whether patients can adhere sufficiently to a high water intake.

DRINK is a single-centre prospective, open label, parallel group randomised controlled feasibility trial. The primary objective is to establish whether a definitive large randomised trial comparing high versus ad libitum water intake on long-term disease progression is deliverable. Fifty patients will be recruited from the Renal Genetics service at Addenbrooke's Hospital. Participants will be randomly allocated to the high water intake (high) or the ad libitum (standard) water intake group. For the high intake group the aim is to drink large enough volumes of water to achieve and maintain dilute urine (urine osmolality \< 270 mOsmo/kg or urine specific gravity ≤ 1.010 ). Multiple methods will be employed to promote adherence these include instruction and education as well as self-monitoring of urine specific gravity twice weekly by participants and the recording of results via a trial specific smartphone application.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autosomal Dominant Polycystic Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ad libitum water intake

Ad libitum water intake, defined as intake guided by thirst to achieve a target urine osmolality \> 300 mOsmo/kg

Group Type ACTIVE_COMPARATOR

Ad libitum water intake

Intervention Type OTHER

Water intake guided by thirst

High water intake

Personalised daily water intake prescription to achieve target urine osmolality \< 270 mOsm/kg.

Group Type ACTIVE_COMPARATOR

High water intake

Intervention Type DIETARY_SUPPLEMENT

High water intake aimed at achieving an urine osmolality \< 270mOsmo/kg. Individualised prescription for each participant based on the free water clearance formula calculation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High water intake

High water intake aimed at achieving an urine osmolality \< 270mOsmo/kg. Individualised prescription for each participant based on the free water clearance formula calculation.

Intervention Type DIETARY_SUPPLEMENT

Ad libitum water intake

Water intake guided by thirst

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have given written informed consent to participate
* Aged 16 years or older
* Have a diagnosis of ADPKD (fulfilling radiological diagnostic criteria ± genetic evidence)
* eGFR ≥ 20ml/min/1.73m2
* Able to self-monitor urine SG

Exclusion Criteria

* Inability to provide informed consent
* eGFR \< 20ml/min/1.73m2
* Fluid overload states e.g. heart failure, cirrhosis, or requirement for fluid restriction
* Confounding illness impacting on renal disease e.g. concomitant diabetes or glomerulonephritis
* Treatment with diuretics for fluid overload (those on diuretics for hypertension may participate in the trial after a run-in period of 2 weeks)
* Treatment with Tolvaptan in the last 4 weeks
* Pregnancy or breastfeeding

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No